Confo Therapeutics

Confo Therapeutics is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. Confo Therapeutics employs its proprietary CONFO® technology to lock inherent unstable functional conformations of GPCRs as a superior starting point for drug discovery. CONFO® body-stabilized active state conformations of these receptors disclose previously inaccessible structural features empowering the discovery of novel agonists for better therapeutic intervention.

Confo Therapeutics headquartered in Europe, operates in the Biotechnology, Health Care, Medical, Therapeutics sector. The company focuses on Biotechnology and has secured $21.1B in funding across 176 round(s). With a team of 51-100 employees, Confo Therapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Venture Round - Confo Therapeutics, raised $3.4M. Discover more about their projects, partnerships, and impact on our platform.